Exact Sciences Expands Colorectal Cancer Screening Partnership with Humana

Exact Sciences has expanded its colorectal cancer screening partnership with Humana, making the Cologuard Plus test available as an in-network service for eligible Humana Medicare Advantage members nationwide starting in August. This partnership aims to enhance access to colorectal cancer screening for approximately 5.8 million Humana Medicare Advantage members.

Exact Sciences has announced an expanded partnership with Humana, making the Cologuard Plus test available as an in-network service for eligible Humana Medicare Advantage members nationwide starting in August 2025. This initiative aims to enhance access to colorectal cancer (CRC) screening for approximately 5.8 million Humana Medicare Advantage members [2].

The Cologuard Plus test, which launched in March 2025, has received FDA approval, Medicare coverage, and inclusion in the U.S. Preventive Services Task Force guidelines. Developed in collaboration with Mayo Clinic, the Cologuard Plus test is a first-line, non-invasive CRC screening option for adults aged 45 or older who are at average risk for the disease [1, 2].

The Cologuard Plus test introduces new biomarkers and enhanced laboratory processes, designed to reduce false positives by more than 40% compared to its predecessor, Cologuard. This reduction in false positives helps minimize unnecessary follow-up colonoscopies, improving overall screening efficiency [1, 2].

Exact Sciences Screening general manager and executive vice-president Jake Orville stated, "The Exact Sciences team is proud to expand access to Cologuard Plus through our collaboration with Humana, making it easier for more people to access this revolutionary, non-invasive colorectal cancer screening test from the comfort of home" [1].

The Cologuard Plus test allows individuals to collect samples at their convenience in their own homes, without the need for any special preparations or time off. Once the sample is collected, it can be sent back to the laboratory for analysis [1].

Both tests are exclusively available in the US. In January 2025, Exact Sciences reported trial results of the Oncodetect test, intended to detect residual cancer cells post-treatment [1].

References:
[1] https://www.medicaldevice-network.com/news/exact-sciences-colorectal-cancer/
[2] https://www.marketscreener.com/news/exact-sciences-corp-and-humana-inc-expand-colorectal-cancer-screening-partnership-with-cologuard-p-ce7c5fdddd80f421